Working together to reduce the global burden of kidney cancer
Kidney cancer is a global issue. Every year, 431,000 people worldwide will be diagnosed with kidney cancer.
Click here for shareable information, graphics and materials about kidney cancer for patient organisations worldwide.
Highlights from the ESMO Virtual Congress 2021
The European Society of Medical Oncology (ESMO) congress was held virtually from 16-21 September 2021. The presentations are available to view on the ESMO website if you have previously logged in to the site. The International Kidney Cancer Coalition (IKCC) attended the virtual scientific programme to keep abreast of the latest advances in the care and treatment of people with kidney cancer.
2021 Global Kidney Cancer Summit
Save the Date: World Kidney Cancer Day 2022
Save the date for the 6th World Kidney Cancer Day on 16 June 2022. Join patients, families, friends, carers, healthcare professionals, researchers and local kidney cancer organisations from around the world coming together to raise awareness of clinical trials and access to treatment. Start conversations about how clinical trials can improve access to new treatments for kidney cancer. To improve the lives of kidney cancer patients worldwide ‘We need to talk’.
Updates from IKCC
Joseph Heisler was 9,when von Hippel-Lindau (VHL) disease entered his life when his father was diagnosed. Soon after, Joseph and his younger brother, Michael would be diagnosed, too,he reflects on Decades of Change for the Rare Condition https://t.co/hge1pwcto6 via @curetoday
This study reported results from the RAPPORT trial, a multi-institutional phase I/II study of radiation delivered to sites of oligometastatic clear cell #kidneycancer followed by 8 cycles of pembrolizumab in patients (2 or fewer prior systemic therapies).
https://t.co/7bfED61xM9
New #JITC review: Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies https://t.co/dM76Holub6 @peters_solange @lalaniMD https://t.co/J9XgrweFbc
This is a phase II study of the HIF-2α inhibitor belzutifan (MK-6482) in 61 patients with VHL syndrome–associated RCC. Safety and Efficacy of Belzutifan for VHL-Associated RCC | comment: Jun Gong MD https://t.co/Bzht3iP0C4 via @practiceupdate
The authors conducted a phase II single-armed trial of stereotactic ablative radiation (SAbR) therapy for patients with metastatic #kidneycancer on systemic therapy with three or fewer sites of progression. https://t.co/XKoskHAmTF via @practiceupdate
Did you know?
Kidney cancer is often found by accident.
Kidney cancer is the 12th most prevalent cancer worldwide.
About 59 per cent of kidney cancer cases occur in more developed countries.
Our Global Network
IKCC welcomes every organisation that has an interest in kidney cancer and who pledges to conform to our Code of Conduct. We extend an open invitation to become part of this international network.
Join our mailing list
In the newsletter we highlight news about kidney cancer diagnosis and treatment, and other relevant discussions.